Clients
Royalty Pharma Sub-Manager serves 7 clients. The average client has about $2.81 billion with the firm.
- Pooled investment vehicles7 clients100%
Show client breakdownHide client breakdown
| Client type | Clients | Regulatory AUM | Share | Avg. per client |
|---|---|---|---|---|
| Pooled investment vehicles | 7 | $19,638,739,455 | 100.0% | $2.81B |
| Total | 7 | $19,638,739,455 | 100% | $2.81B |
- Clients
- 7
- Regulatory AUM
- $19,638,739,455
- Share
- 100.0%
- Avg. per client
- $2.81B
Total
- Clients
- 7
- Regulatory AUM
- $19,638,739,455
- Share
- 100%
- Avg. per client
- $2.81B
What it does
Royalty Pharma Sub-Manager provides portfolio management for pooled vehicles. It is paid through a percentage of assets, fixed fees, performance-based fees and other arrangements.
Royalty Pharma Sub-Manager provided financial planning to 0 clients last fiscal year and advises 2 private funds.
100.0% of assets ($19.64B across 7 accounts) are managed with discretion. 86% of clients are outside the U.S., and 0 clients received advice without assets under management last fiscal year.
Custodians
Royalty Pharma Sub-Manager has custody of $19.63B for 5 clients.
- All other custodians$19.64B100%
Ownership and leadership
Royalty Pharma Manager, LLC owns 75% or more of Royalty Pharma Sub-Manager, and Pablo Legorreta is its CEO.
- Owns 75% or more of Royalty Pharma Sub-Manager, LLC
Royalty Pharma Manager, LLC
Control person · since May 2025
- Owns 75% or more of Royalty Pharma Manager, LLC
Royalty Pharma Holdings LTD
Control person · since May 2025
- Owns 50% to 75% of Royalty Pharma Holdings LTD
Royalty Pharma PLC
since May 2025
Leadership
- Pablo LegorretaChief Executive Officer
- Terrance CoyneExecutive Vice President and Chief Financial Officer
- Arthur McGivernExecutive Vice President and General Counsel
- Carolyn RubinChief Compliance Officer
Staff
- 91 employees
- 48 in advisory functions
Reported holdings
Royalty Pharma Sub-Manager’s reported 13F holdings total $241.9M across 4 positions, and the ten largest make up 100.0% of it.
- $241.9M
- Reported 13F value
- 4
- Positions
- 100.0%
- In the 10 largest
- +40.0%
- Value vs. prior quarter
- Cytokinetics, Inc.34.5%
- Zenas Biopharma, Inc..25.1%
- Kailera Therapeutics22.4%
- Biohaven Ltd18.1%
Together, the ten largest are 100.0% of reported value.
A 13F covers only exchange-traded long positions the firm holds with discretion, so this $241.9M is not its $19.64B in regulatory assets and does not represent any individual client's portfolio.
Fees
Royalty Pharma Sub-Manager is paid through a percentage of assets under management, fixed fees (other than subscription fees), performance-based fees and other.
Royalty Pharma Sub-Manager’s fee rates are not included in this profile. Find its brochure on the SEC’s site.
Offices and registrations
Besides its headquarters, Royalty Pharma Sub-Manager has 0 offices, with 1 listed address in 1 state.
New York · 1 listed address
- 110 East 59th Street, New YorkHQ
Registration details
- Legal name
- Royalty Pharma Sub-Manager, LLC
- Headquarters
- 110 East 59th Street, New York, NY 10022
- Phone
- 212-883-0200
- Website
- royaltypharma.com
- SEC file
- 801-132133
- Structure
- Delaware LLC
- Fiscal year end
- December
This directory does not report disciplinary history, for any firm or individual, in either direction. The SEC publishes the complete record, including any disciplinary events, and it is the authoritative place to check one. See this firm's record on adviserinfo.sec.gov
Common questions
How many clients does Royalty Pharma Sub-Manager have?
Royalty Pharma Sub-Manager has 7 clients and manages $19.6 billion for them, as of May 2026.
Source: Form ADV Part 1A, Items 5.D and 5.F, filed 4 May 2026
What services does Royalty Pharma Sub-Manager offer?
Royalty Pharma Sub-Manager provides portfolio management for pooled vehicles.
Source: Form ADV Part 1A, Item 5.G, from the SEC's 2 October 2026 data file
How many financial advisors does Royalty Pharma Sub-Manager have?
Royalty Pharma Sub-Manager has 0 investment adviser representatives registered with state securities authorities, out of 91 employees, and 48 perform investment advisory functions. None are registered representatives of a broker-dealer or licensed insurance agents.
Source: Form ADV Part 1A, Items 5.A and 5.B, from the SEC's 2 October 2026 data file
Who owns Royalty Pharma Sub-Manager?
Royalty Pharma Sub-Manager is owned through a chain of holding companies by Royalty Pharma PLC. Its direct owner is Royalty Pharma Manager, LLC (75% or more).
Source: Form ADV Part 1A, Schedules A and B, filed 4 May 2026
How does Royalty Pharma Sub-Manager get paid?
Royalty Pharma Sub-Manager is paid through a percentage of assets under management, fixed fees, performance-based fees and other arrangements. Its Form ADV lists no commissions among how it is paid.
Source: Form ADV Part 1A, Item 5.E, from the SEC's 2 October 2026 data file